In the Test group, one patient administered an unscheduled seventh unsupervised injection a day before the Study Completion visit, which was therefore rescheduled for a month later.
Adequate assessment of selective reporting among registered test accuracy studies proved difficult: only a quarter of the registered studies 4% of all published studies had been registered before initiation, and only one-third of the registered studies 5% of all published studies had registered the published primary outcomes before the study completion date.
Of the 620 adults who initially enrolled in the trial, 208 of whom regularly used heroin as well as cocaine, almost half dropped out before the study's completion, as is common in studies of addiction treatment.
A larger proportion of patients in the febuxostat arms than in the allopurinol arm discontinued the interventions before study completion: 88 (34%) with febuxostat 80 mg/day, 98 (39%) with febuxostat 120 mg/day, and 66 (26%) with allopurinol.
Second, more patients in the GPB than in the placebo arm exited before study completion, a finding likely resulting from the fact that more Child-Pugh class C patients were randomized to GPB.
Sixty-four subjects in the colesevelam group withdrew before study completion, relative to 90 subjects in the placebo group.
The bottles were weighed before and after study completion to determine the total quantities actually used.
The impact of enrolling many patients who will die within 90 days, frequently before study completion, on the effective delivery of phase I trials should also be better evaluated.
48 Five percent of patients receiving azacitidine discontinued treatment in the AZA-001 trial before study completion owing to hematological adverse events.
Biased selection for publication may affect research dissemination over the whole process from before study completion, to presentation of findings at conferences, manuscript submission to journals, and formal publication in journals.
Patients returned to the clinic site for visits 1, 2, 8 and 12 weeks after the baseline visit, and a follow-up call was scheduled for week 16, or 30 days after the end of treatment if the investigational product was discontinued before study completion.
